We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.
- Authors
Roberts, Andrew W; Seymour, John F; Brown, Jennifer R; Wierda, William G; Kipps, Thomas J; Khaw, Seong Lin; Carney, Dennis A; He, Simon Z; Huang, David C S; Xiong, Hao; Cui, Yue; Busman, Todd A; McKeegan, Evelyn M; Krivoshik, Andrew P; Enschede, Sari H; Humerickhouse, Rod
- Abstract
BCL2 overexpression is a hallmark of chronic lymphocytic leukemia (CLL). The novel BH3 mimetic navitoclax (ABT-263) specifically inhibits BCL2 and related proteins BCL-x(l) and BCL-w, potently inducing apoptosis of CLL cells in vitro. A phase I trial in patients with CLL was conducted to evaluate the safety, pharmacokinetics, and biologic activity of oral navitoclax.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Vol 30, Issue 5, p488
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2011.34.7898